Overview

Cardiomyopathy is a general term for disorders that primarily affect the myocardium, the muscle of the heart. When the heart muscle becomes weak, thickened, rigid, or otherwise abnormal, its ability to pump and fill with blood is impaired. People with cardiomyopathy are frequently at increased risk of arrhythmia and, in some cases, sudden cardiac death. The clinical picture ranges from silent disease discovered incidentally to progressive heart failure or life‑threatening rhythm disturbances.

Types and characteristic features

Clinicians classify cardiomyopathies by their predominant structural or functional pattern. The principal categories include:

  • Dilated cardiomyopathy — enlargement of one or both ventricles with reduced pumping function.
  • Hypertrophic cardiomyopathy — thickening of the heart muscle, often the septum, which can obstruct outflow and disturb relaxation.
  • Restrictive cardiomyopathy — stiff ventricles that resist filling despite relatively preserved contraction.
  • Arrhythmogenic cardiomyopathy — progressive replacement of heart muscle by fibrous or fatty tissue, often affecting the right ventricle and predisposing to arrhythmias.

Other recognized forms include stress‑related (takotsubo) cardiomyopathy, infiltrative types (for example due to amyloid), and myocarditis‑related dysfunction. Some cases are labelled primary (originating in the heart) and others secondary to systemic disease.

Causes, presentation, and diagnosis

Causes vary: inherited genetic mutations, viral infections, autoimmune processes, toxins (including alcohol and some chemotherapy agents), metabolic disorders, and pregnancy can all play a role. Symptoms commonly include breathlessness on exertion, fatigue, swelling of the legs, palpitations, chest discomfort, or fainting. Physical findings and symptoms overlap with other cardiac conditions, so evaluation typically combines electrocardiography, echocardiography, cardiac magnetic resonance imaging, blood tests, and sometimes endomyocardial biopsy or genetic testing to define cause and extent.

Management and prognosis

Treatment aims to relieve symptoms, prevent progression, and reduce the risk of arrhythmia and sudden death. Standard measures include medications (such as agents to reduce workload on the heart, control rhythm, or remove excess fluid), device therapy (implantable cardioverter‑defibrillators, pacemakers, or cardiac resynchronization), catheter procedures for arrhythmia control, and mechanical circulatory support for advanced failure. In refractory cases, heart transplantation may be considered. Prognosis is highly variable and depends on the type, severity, underlying cause, and response to therapy; family screening and lifestyle modifications are often recommended.

History, research, and important distinctions

The concept of cardiomyopathy emerged as clinicians recognized heart muscle disorders not explained by coronary artery disease or valvular defects. Advances in imaging, molecular genetics, and cellular biology have clarified many inherited forms and helped develop targeted care. Important distinctions include cardiomyopathy versus ischemic heart disease (where narrowed arteries cause muscle damage) and primary versus secondary forms. Because some types carry a genetic risk, relatives of affected individuals may be offered evaluation and counseling.

Notable facts

  • Cardiomyopathy is a leading cause of heart transplantation and a frequent contributor to chronic heart failure.
  • Risk of dangerous arrhythmias makes prompt diagnosis and individualized risk assessment central to care; devices such as an implantable cardioverter‑defibrillator can be life‑saving in selected patients.
  • Ongoing research focuses on gene‑based diagnostics, novel pharmacologic targets, and improved mechanical support technologies.